nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-6A1B4418·Framework v5.0·Pipeline v0.4·Evaluated 08 Jul 2026·OECD: 3.2 Clinical medicine·Subfield: Molecular Biology·Basis: Full text·Type: Meta-analysis

Appraising clinicopathological and prognostic significance of circular RNA ubiquitin-associated protein 2 in human cancer.

Luo et al.Luo, Tian, Hader et al.·2025·World journal of surgical oncology·10.1186/s12957-025-04118-0 ↗

In brief

A competent first circUBAP2 biomarker synthesis that organizes scattered cancer evidence, but its pan-cancer inference remains preliminary.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

BACKGROUND: Circular RNA ubiquitin-associated protein 2 (circUBAP2) is highly expressed in various human cancers and has been identified as a key contributor to cancer development and progression. We performed this study to explore the clinicopathological and prognostic significance of circUBAP2 in multiple cancers. METHODS: This meta-analysis was conducted according to PRISMA 2020 guidelines. PubMed, Web of Science, CNKI, Wanfang, ClinicalTrials.gov and BioXiv were systematically searched from inception to March 1, 2025 according to the PICO framework. Study quality was appraised using the Newcastle-Ottawa Scale and eventually a total of 12 studies with 905 participants were included. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were synthesized using fixed- or random-effects models based on heterogeneity (I² statistic) to evaluate the association of circUBAP2 with age, sex, tumor size, stage, differentiation and metastasis. The stability of the results from meta-analysis was estimated via sensitivity analysis. Begg’s funnel plots and Egger’s test were used to appraise the potential publication bias. Subgroup analysis for overall survival (OS) based on follow-up duration, tumor type, case number and survival endpoints were also performed. RESULTS: High expression of circUBAP2 was significantly related to larger tumor size (OR = 3.07, 95% CI: 1.53–6.17, P < 0.05), advanced stage (OR = 2.43, 95% CI: 1.70–3.48, P < 0.05), poor differentiation (OR = 4.47, 95% CI: 2.67–7.48, P < 0.05) and metastasis (OR = 5.77, 95% CI: 3.21–10.40, P < 0.05), but not associated with age or sex. Additionally, circUBAP2 was related to cancer survival (HR = 2.43, 95% CI: 1.96–3.03, P < 0.05), regardless of follow-up duration, tumor type, case number, and survival endpoints. Begg’s funnel plot and Egger’s test showed no publication bias. CONCLUSIONS: High expression of circUBAP2 may predict larger tumor size, poor differentiation, distant metastasis and poor outcome of cancer, highlighting the carcinogenetic role of circUBAP2 in human cancer.

Strengths · Limitations

Strengths

#contribution

First synthesis of circUBAP2 evidence

The Introduction identifies the absence of prior meta-analysis on circUBAP2 in human cancer, and the Results aggregate 12 studies covering clinicopathological features and survival outcomes. This gives the paper a clear role as an initial evidence map for a narrow biomarker question.

↳ Introduction; Results, Characteristics of Included Studies; Table 1

#methodological rigour

Core systematic-review procedures reported

The Methods state OSF registration, PRISMA checklist use, searches across PubMed, Web of Science, CNKI, Wanfang, ClinicalTrials.gov, and BioXiv, plus dual screening and extraction with adjudication. These features support a competent baseline evidence-synthesis workflow.

↳ Methods, Search Strategies; Methods, Selection Process; Methods, Data Extraction

#positioning

Limitations are explicitly acknowledged

The Discussion identifies a small total evidence base, survival information extracted from curves, and underpowered cancer-specific strata. This helps readers interpret the pooled pan-cancer estimates as preliminary rather than definitive.

↳ Discussion, Limitations

Limitations

#methodological rigour

Certainty framework is missing

The review does not report GRADE or an equivalent certainty-of-evidence assessment despite drawing clinically relevant prognostic conclusions. This limits how clearly readers can distinguish statistical significance from confidence in the evidence base.

↳ Methods; Results; Discussion

#application pathway

Pan-cancer pooling limits clinical specificity

The included studies span multiple tumor types with small individual strata, and some outcomes are represented by only one or two studies. The broad pooled associations therefore do not establish reliable tumor-specific clinical utility.

↳ Results, Table 1; Results, Table 3; Discussion, Limitations

#reporting

Reporting precision has notable lapses

The Search Process exclusion counts do not reconcile exactly, Table 3 uses a fixed-effects model for a subgroup with I²=52.5% despite the stated model rule, and the Discussion contains awkward or garbled wording. These issues do not overturn the main results but reduce confidence in reporting discipline.

↳ Results, Search Process; Methods, Statistical Analysis; Table 3; Discussion

Does this match your read? Add your assessment ↓

Nabu Commentary

The adjudicated quality score reflects a competent but not best-practice systematic review. The strongest elements are the registered PRISMA-framed workflow, dual review processes, and clear presentation of pooled clinicopathological and survival associations in Tables 2–3 and Figures 3–6. The main methodological constraints are the absence of a formal certainty assessment, sparse and heterogeneous retrospective evidence, survival-curve extraction, and limited reproducibility of data or code. The UBAP2/TCGA analysis is transparently described as indirect because TCGA lacks matching circRNA annotations, but it still adds interpretive complexity rather than strengthening the core circUBAP2 synthesis.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.1±0.2

Contribution
3.1

The study addresses a real synthesis gap by aggregating the clinicopathological and prognostic literature on circUBAP2 across human cancers. The contribution is modest because it is a narrow single-biomarker meta-analysis based on 12 retrospective studies and 905 participants.

Introduction; Results, Characteristics of Included Studies; Table 1

no meta-analysis has been performed

Methodological Rigour
3.0

The methods include OSF registration, PRISMA alignment, six searched sources, dual screening/extraction, NOS assessment, sensitivity analysis, and publication-bias checks. The score is limited by absence of GRADE, small-study publication-bias testing, incomplete search/data/code reproducibility, survival-curve extraction, and an effects-model inconsistency in Table 3.

Methods, Search Strategies; Methods, Statistical Analysis; Results, Search Process; Table 3; Discussion, Limitations

Meta-regression was not feasible due to limited number of studies

Reporting
3.2

The article follows a conventional systematic-review structure and presents the main pooled estimates in tables and figures. Reporting is reduced by duplicated sensitivity-analysis wording, awkward or garbled phrasing, and occasional stronger causal or mechanistic language than the meta-analysis directly supports.

Methods, Statistical Analysis; Results, Sensitivity Analysis; Abstract Conclusions; Discussion

highlighting the carcinogenetic role

Positioning
3.2

The Discussion situates circUBAP2 within conflicting mechanistic and cancer-type-specific literature and explicitly acknowledges small sample size, curve-extracted survival data, and underpowered strata. Contextual strength is moderated by the use of linear UBAP2 TCGA analysis as supporting context for circUBAP2 and by limited formal certainty-of-evidence framing.

Discussion; Methods, Prognostic Significance of UBAP2 in TCGA Dataset; Table 4

CircRNA annotations were unavailable for TCGA cohorts

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The paper is broadly internally interpretable and the main pooled estimates are consistently reported, but several reporting issues reduce confidence in exactness. These include inconsistent exclusion arithmetic, an effects-model inconsistency in one survival subgroup, overconfident publication-bias language, and minor citation/editing problems.

Research ConductNoted

The review reports OSF registration, PRISMA alignment, dual screening, and dual extraction, but reproducibility and conduct reporting are incomplete. Data and code availability are not provided, conflict-of-interest reporting is not visible in the supplied text, and protocol-to-report consistency cannot be verified from the article alone.

Flags: 1 declared / 5 total

Reference IntegrityClean

All 31 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Other malignant neoplasms
Type of advanceSynthesis
Route to useSuggested
AdvanceExtends
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The meta-analysis pools 12 small single-center studies with 905 patients, providing proof-of-concept prognostic association but no independent large-scale or multi-center validation.

From the paper
“circUBAP2 might be a candidate target with prognostic significance in human cancer”

The paper names a possible real-world use of its findings as a prognostic biomarker or target in cancer, but does not specify who would act on it or in what setting.

Pathway

Oncologists and cancer diagnostic developers could use circUBAP2 expression as a prognostic biomarker to stratify patients for intensified treatment or follow-up.

Barrier

The pooled evidence rests on only 905 patients across small heterogeneous studies, and the paper itself calls for multi-center high-quality studies to validate the findings.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression

    Min-Cheng Yu, Guang-Yu Ding, Peng Ma, et al. · 2021 · Clinical medicine

    Evidence Score
    3.2±0.2
    Reliability
    Caveats
  2. Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496

    Fu, Liu, Zhao, et al. · 2023 · Clinical medicine

    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  3. CircUBAP2 Promotes MMP9-Mediated Oncogenic Effect via Sponging miR-194-3p in Hepatocellular Carcinoma

    Liu, Tian, Chen, et al. · 2021 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    Caveats

How the rubric works →